global stem cell market - brief overview

www.indiabusinessreports.com

Global Stem Cell MarketTechnology & Global Market Opportunity

Sector: Pharma / Healthcare Services

May 2014

2

Index

What are Stem Cells? 3

Types of Stem Cells and their Relative Merits 8

Status of Stem Cell R&D 16

Global Stem Cell Market Size 23

Leading Global Stem Cell Companies 30

Indian Stem Cell Companies 42

Deals in Stem Cell Space 45

www.indiabusinessreports.com Global Stem Cell Market

What are Stem Cells?


4Global Stem Cell Market

Stem Cell Definition

• Stem cells are fundamental, basic, or undifferentiated cell of a multi-cellular organism. They are capable of being transformed or grow into indefinitely manifold cells of the same type, and from which, other kinds of cell can be grown, by differentiation

• Stem cells are at the center of a new field of science called Regenerative Medicine.

• Since stem cells can become a bone, muscle, cartilage and other specialized types of cells, they have the potential to treat many diseases, including Parkinson's, Alzheimer's, diabetes and cancer.

– They may also be used to regenerate organs / skin, reducing the need for organ transplants and related surgeries.



Types of Stem Cells

There are three broad categories of stem cells• Embryonic stem cells

– Embryonic stem cells include those found within the embryo, the fetus or the umbilical cord blood. Depending upon when they are harvested, embryonic stem cells can give rise to just about any cell in the human body.

• Adult / Tissue stem cells– Adult stem cells can be found in infants, children and adults. They reside in

already developed tissues such as those of the heart, brain and kidney. They usually give rise to cells within their resident organs.

• Induced pluripotent stem cells (IPSC)– These stem cells are adult, differentiated cells that have been experimentally

"reprogrammed" into a stem cell-like state.



Why Interest in Stem Cells

• Increase understanding of how diseases occur– By watching stem cells mature into cells that eventually become bones, heart

muscle, nerve cells, and other organs and tissue, researchers and doctors will have better understanding how a variety of diseases and conditions develop.

• They have the ability to generate healthy cells to replace diseased cells (regenerative medicine)– Researchers believe that they can train stem cells into becoming specific cells

so that those specialized cells can be used to regenerate and repair diseased or damaged tissues in people.

• Test new drugs for safety and effectiveness.– Before using new drugs in people, researchers could use stem cells to test the

safety and quality of investigational drugs. – For instance, nerve cells could be generated in order to test a new drug for a

nerve disease. Tests could show whether the new drug had any effect on the cells and whether the cells were harmed.



Stem Cell Market Business Segmentation

Stem cell market can be segmented in four segments

• Stem Cell Products– Adult stem cell, cord blood cells, human embryonic cells and other

• Stem Cell Services – Stem cell banking, stem cell acquisition and testing, drug discovery and target

identification, isolation / characterisation services, and molecular biology• Stem Cell Technologies

– Stem cell production, cryopreservation, expansion and sub-culture• Stem Cell Applications

– Regenerative medicine – neurological disorders, orthopedics, cancer hematological disorder, incontinence, and drug development


Type of Stem Cells and Their Relative Merits


9

Popular Sources of Stem Cells


11%

33%

5%5%6%

11%

17%

6%6%

Cell TypeAdiposeBone MarrowEmbryonicEpithelialFibroblastsMesenchymalNeuralPlacentalUnfertilised eggs

Source: www.seekingalpha.com


Type of Stem Cells and Their Current Uses – Snap Shot


Type Source Their capability

Current researches

Clinic readiness?

Advantages Limitations

Embryonic Stem Cells

Early stage embryo called a blastocyst

Make all the different types of cells in our body

Understanding how our bodies develop from a fertilized egg; Investigating how to produce different types of specialised cell

The first clinical trials are now beginning, focussed on treating eye disorders; these are early stage safety trials

Can produce all the different types of cells in the body . Can self-renew (copy themselves) almost forever, so large supplies can be made

Still learning how to fully control differentiation of these cells. Some concerns on ethical or religious grounds

Tissue stem cells (e.g. skin, blood)

Tissues of the adult body

Make only the types of cells that belong in their own tissue, e.g. skin stem cells make only types of skin cells, they do not make brain or blood cells

Understanding how adult tissues are made and maintained Improving our understanding of diseases affecting adult tissues, including cancer

Skin and blood stem cells have been in use for a number of years for skin grafts and bone marrow transplants

Already partly specialised, which can make it more straightforward to obtain the particular specialised cell type required

How to multiply, control and use different types of tissue stem cells. Treatments for blood diseases, severe burns and some types of corneal damage have been proven; no other treatments are yet proven.


Type of Stem Cells and Their Uses – Snap Shot



Current researches

Clinic readiness? Advantages Limitations

Umbilical Cord Blood Stem Cells

The umbilical cord after the birth of a baby

Make the different types of cells found in the blood

Understanding how blood stem cells work

Mainly used to treat children with blood disorders, primarily leukaemia; although adults can sometimes be treated, this is limited because only a small number of stem cells can be obtained from a cord

Can be frozen and stored

Need to know how to multiply cord blood stem cells. Only proven uses are for blood disorders; studies suggesting these cells can be used to make non-blood-related types of cells have not been widely reproduced Cord blood must be matched to the patient to avoid rejection.

Mesen-chymal stem cells (a type of tissue stem cell)

Bone marrow Make cells of the skeletal tissues: bone, cartilage, fat Support blood stem cells to make new blood cells

Understanding how these cells contribute to making and maintaining tissues

Clinical trials are underway for cartilage & bone repair, for aiding repair of blood vessels after heart attacks, and for other unrelated treatment

Already partly specialised, which can make it more straightforward to obtain the particular specialised cell type required

How to multiply, control and use different types of tissue stem cells. Treatments for blood diseases, severe burns and some types of corneal damage have been proven; no other treatments are yet proven.


Type of Stem Cells and Their Uses – Snap Shot



Current researches

Clinic readiness? Advantages Limitations

Induced Pluripotent stem cells (iPS cells)

Made in the lab from specialized adult cells, for example skin cells

Behave very like embryonic stem cells – make all types of cells in the body

Can be made from patients and used to produce cells that act as a model “disease in the laboratory” for studying diseases and testing new drugs

Not yet Could provide patient-specific treatment

Not yet established how reprogramming works . Properties of cells need further comparison with embryonic stem cells As with ES cells, we are still learning how to fully control these cells to ensure they make the cells we want in a way that will be safe for clinical use


Diseases Curable by Cord Blood Stem Cells


Cancer Blood Disorders Immune Disorders Metabolic Disorders

1. Acute Leukemia2. Chronic Leukemia3. High-Risk Solid

Tumors4. Hodgkin & Non-

Hodgkin Lymphoma (types of blood cancers)

5. Myelodysplastic Syndromes *

1. Aplastic Anemia2. Beta Thalassemia3. Diamond-Blackfan

Anemia4. Fanconi Anemia#5. Sickle Cell Disease

1. Chronic Granulomatous@ Disease

2. Hystiocytic Disorders$3. Leukocyte Adhesion

Deficiency%4. Severe Combined

Immunodeficiency Diseases

5. Wiskott-Aldrich Syndrome^

1. Krabbe Disease&2. Hurler Syndrome+3. Metachromatic£

Leukodystrophy4. Sanfilippo Syndrome

* Syndromes involving ineffective production of the myeloid class of blood cells. Patients with MDS can develop severe anemia and require blood transfusions# A genetic defect in a cluster of proteins@ A genetic disorder in which certain immune system cells are unable to kill some types of bacteria and fungi$ Histiocytic disorders are a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation% A rare autosomal recessive disorder characterized by immunodeficiency resulting in recurrent infections^ Wiskott–Aldrich syndrome is a rare X-linked recessive disease characterized by eczema, thrombocytopenia, immune deficiency, and bloody diarrhea& Krabbe disease is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system.+ Hurler syndrome is a genetic disorder due to a deficiency of alpha-L iduronidase, an enzyme responsible for the degradation of mucopolysaccharides in lysosomes£ Hurler syndrome is a genetic disorder due to a deficiency of alpha-L iduronidase, an enzyme responsible for the degradation of mucopolysaccharides in lysosomes


Diseases Curable by Adult Stem Cells


Cancer Cancer Auto-Immune Disorders

Anemias/Blood Conditions

1. Brain Cancer2. Retinoblastoma3. Ovarian Cancer4. Skin Cancer:

Merkel Cell Carcinoma

5. Testicular Cancer6. Tumors abdominal

organs Lymphoma7. Non-Hodgkins

lymphoma8. Hodgkins

Lymphoma9. Acute

Lymphoblastic Leukemia

10. Acute Myelogenous Leukemia

11. Juvenile Myelomonocytic Leukemia

12. Cancer of the lymph nodes

13. Multiple Myeloma14. Myelodysplasia15. Breast Cancer16. Neuroblastoma17. Renal Cell Carcinoma18. Various Solid Tumors19. Soft Tissue Sarcoma20. Waldenstrom's

macroglobulinemia21. Hemophagocytic

lymphohistiocytosis22. POEMS syndrome

1. Multiple Sclerosis2. Crohn's Disease3. Scleromyxedema4. Scleroderma5. Rheumatoid Arthritis6. Juvenile Arthritis7. Systemic Lupus8. Polychondritis9. Sjogren's Syndrome10. Behcet's Disease11. Myasthenia12. Autoimmune

Cytopenia13. Systemic vasculitis14. Alopecia universalis

1. Sickle cell anemia2. Sideroblastic anemia3. Aplastic Anemia4. Amegakaryocytic

Thrombocytopenia5. Chronic Epstein-Barr

Infection6. Fanconi's Anemia7. Diamond Blackfan

Anemia8. Thalassemia Major9. Red cell aplasia10. Primary

Amyloidosisme


Diseases Curable by Adult Stem Cells


Wounds/Injuries Neural Degenerative Diseases/Injuries

Immunodeficiencies Other Metabolic Disorders

1. Limb gangrene2. Surface wound

healing3. Jawbone

replacement4. Skull bone repair

1. Parkinson's disease2. Spinal cord injury3. Stroke damage

1. X-Linked hyper immunoglobuline-M Syndrome

2. Severe Combined Immunodeficiency Syndrome

3. X-linked lymphoproliferative syndrome

1. Osteogenesis imperfecta

2. Sandhoff disease3. Hurler's syndrome4. Krabbe Leukodystrophy5. Osteopetrosis6. Cerebral X-linked

adrenoleukodystrophy

Other diseases that can be cured are repairing heart damage and corneal regeneration

Status of Stem Cell R&D


17

Stem Cell therapies – At the Cusp of Emerging

The cell therapy sector, is currently engaged in over 1,900 clinical trials around the world. This includes more than 300 clinical trials being sponsored by approximately 250 companies developing commercial products for almost every imaginable disease or condition.

In 2012, the sector garnered over $900 million in investment from private investors and public markets, and over $300 million from grant sources aggregating an approximate $1.2 billion in investment.


18

Global Pharma investing in Regenerative Med


100% of the companies interviewed in ARM’s Pharma and Biotech Survey are investing in regenerative medicine

19

Key therapeutic opportunities


Industry sees Wound and Burns as the biggest opportunity area, followed by neuro, autoimmune, ocular and cardio vascular diseases

20

Stem cell based new drug candidates the key focus


69% of the companies have invested in cellular-based regenerative medicine products

21

Over 50 late stage trials


Cancer, Musculo skeletal , and non healing wounds would see a spate of new products

22

Korea leads Asia in stem cell research pipeline


Global Stem Cell Market Size


24

Over 100 cell therapy products in the market currently


25

Wound care products are a large share


Non healing wounds, and skin are almost half the productsThe first of these products, Apligraf, was brought to market in 1998.In the past five years there have been 12 approvals: United States (six), Europe (one), Canada (one), New Zealand (one), and South Korea (three).

Source: ARM

26

Small market size currently; immense potential ahead


In 2013, Regenerative Medicines surpassed $1 billion in annual revenue, with over 160,000 patients receiving treatment

In addition, over 60,000 stem cell transplants annually performed worldwide for the treatment of oncology and blood-based disorders

The potential savings from regenerative medicine treatments—for the United States alone—in terms of reducing the direct costs associated with chronic diseases have been estimated at approximately $250 billion a year.


Stem Cell Business Opportunity – Global

• According to Axis Research Mind, global stem cell market was estimated to be $ 21 billion in 2010– Estimated to reach $ 60 billion by 2015

• North America constitutes 60% of the global market, however its the Asian market which is growing faster– Asian markets are estimated to grow at 25% CAGR during the period 2010-

2015• In the Asian region, Japan, China, Singapore, Korea and Australia are the

major hubs for stem cell research



Umbilical Cord Blood Business Opportunity – Global

• Allied Market Research estimates that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012

• Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth.

• The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4%during 2013 to 2020.

• The stem cell storage service market was valued at $7.4 billion in 2013


29

Indian stem cell banking market

Cord Blood Stem Cell Banking has emerged as new opportunity of healthcare services provider in Indian market. The market is still in nascent stage of development and valued around US$ 60 Million in 2013 and further expected to surpass US$ 400 Million by 2018. The current cord blood stem cell preservation level for new born baby is below 1% and hence there exists immense opportunity for cord blood stem cell preservation service providers to grow exponentially in coming years.


http://wn.com/Indian

http://wn.com/The_market

http://wn.com/US$_60

http://wn.com/US$_400

Key Global Companies in Stem Cell Market


31

A vibrant market

They are developing: cell-based therapies, small molecules,

biologics, tissue-engineered cells and materials and implantable devices

drug discovery or toxicity testing tools as well as clinical tools, bioprocessing tools and platforms that include equipment, consumables, reagents and storage systems

The field also incorporates a variety of service companies specializing in clinical trial management, manufacturing, engineering and financing among others.


Alliance for Regenerative Medicine (ARM) estimates there are over 700 companies with a regenerative medicine focus ranging from divisions of multinational corporations to smaller organizations focused solely on the sector.

32

Listed Therapeutic Companies

www.indiabusinessreports.com Global Stem Cells Market

Several listed stem cell companies. All are still in investment mode, with R&D spends much higher than revenue Most of them have products in Phase II or later stages

Company Name Market Cap Revenue (2013)

R&D Exp EBITDA Net Income Employees Founded

1 Mesoblast Inc 1,460.1 32.6 40.1 -55.8 -57.7 76 2004

2 Osiris Therapeutics Inc 444.5 24.3 5.0 -2.8 -1.1 70 1992

3 Neuralstem, Inc., 355.2 0.1 7.1 -12.5 -19.8 15 1996

4 Pluristem Therapeutics Inc 235.4 0.7 17.2 -22.2 -21.2 160 2001

5 Athersys, Inc. 225.3 2.4 20.5 -24.5 -30.7 56 1995

6 NeoStem, Inc 197.2 14.7 16.9 -36.8 -40.0 108 1980

7 Cytori Therapeutics, Inc 187.9 12.2 17.1 -30.7 -26.2 115 1996

8 Fibrocell Science, Inc 165.0 0.2 12.6 -30.5 -30.0 58 1995

9 TiGenix NV 161.5 5.9 15.0 22.1 -25.4 19 2000

10 Advanced Cell Technology 161.0 0.2 11.6 -29.7 -30.6 38

11 Invivo Therapeutics Holdings Corp 120.9 - 10.5 -19.0 -38.8 70 2005

12 StemCells, Inc 71.5 1.2 20.5 -28.6 -26.4 58 1988

13 Cytomedix, Inc. 68.1 11.6 3.8 -18.1 -20.2 40 1987

Source: Stem Cell Stock Index, finance.yahoo.com

33

Mesoblast( Aus): World’s leading stem cell company


Set up in 2004. Did an IPO in Dec’04. Raised $175mn in Mar’13, via a private placement Acquired the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics in

Oct’13. Acquired US company Angioblast in 2010 at A$250mn valuation Has 110 patents nowStem Cells – working with 4 types Mesenchymal Precursor Cell; Culture expanded Mesenchymal Stem Cells; Dental Pulp Stem Cells; Expanded ‐

Hematopoietic Stem CellsTherapeutic areas10 leads across 4 areas: Inflammatory, Spine, Cardio and OncoPhase III CHF (n=1700) (partnership with Teva) Phase III spinal fusion (expected 2014) Phase III Prochymal in GvHD and Crohn’s Disease Degenerative Disc Disease (expected PIII in 2014) Phase II type II diabetes Phase II Rheumatoid Arthritis Phase II Macular degenerationAlliancesTeva: To commercialise adult cells for degenerative conditions of the cardio and CNSLonza: To ensure commercial scale-up, COGS reduction and clinical manufacturing JCR Pharmaceuticals (Japan): For use of MSCs in Graft versus Host disease programmes in children and adults

34

Osiris, USA


Founded in 1992, did IPO in 2006 Developed the world’s first approved stem cell drug, remestemcel-L (brand name

Prochymal) for graft versus host disease, which got approval in Canada Sold Prochymal to Mesoblast in 2013 in a deal worth $100mn + royalties. Sold Biosurgery product Osteocel to Nuvasive, Inc. in 2008 for ~$80 million Now focussed on Biosurgery: wound care, orthopedic and sports medicine markets. Has 3 commercial products, focussed on developing revenues. In 2014, for the first time in

the company’s history, commercial investments will exceed R&D investments From inception in December 1992 through December 31, 2013, Osiris has incurred

aggregate research and development costs of approximately $436 million

Stem Cells – Was using Adult Bone Marrow cells for Prochymal Current products based on human tissue

Curent Therapeutic areas•Grafix: Diabetic foot ulcers and burns•Ovation: Wound healing•Ovation OS: Bone repair•Cartiform: Cartilage restoration

35

Neuralstem, USA: Leader in Neural Stem Cell Science


Founded in 1996, listed in 2006 Raised $20mn in Jan’14, has warrants outstanding for a similar amount Neuralstem is growing regionally specific cells that are already suited to the task prescribed

to them once transplanted into the CNS 15 U.S. patents re-affirmed worldwide – technology and product; 9 pending

Stem Cells Patented technology for isolation and expansion of Neural stem cells

Curent Therapeutic areasAmyotrophic Lateral Sclerosis (ALS): Phase II trials commenced in Sep’13Ischemic Stroke: Phase II trials commenced in Dec’13Spinal Cord Injury: Phase I trials expected to commence in Apr’14Multiple Sclerosis, Optic Neuritis, Alzheimer’s Disease: In pre-clinical phase

36

Pluristem, Isreal: Leader in placenta based cell science


Founded in 2001, listed in 2007 28 granted patents and over 100 pending applications globally

Stem Cells Utilizes PLacental eXpanded (PLX) mesenchymal like adherent stromal cells Treatment of a

variety of inflammatory and ischemic conditions

Therapeutic areas – has around 20 products in its pipeline spanning Cardio – 5 products Ortho – 2 products Pulmonary – 2 products Women’s health – 1 product Hematology – 4 products CNS – 3 products

Alliances With United Therapeutics, Inc for a Pulmonary Hypertension product. Has already

received $7mn upfront payment, and in line to receive $55mn milestone payments With CHA Bio & Diostech, a Korean company, for CLI trials and 50:50 JV in S Korea


Athersys, USA

Founded in 1996, went public through reverse merger in 2007 and raised $ 65 mn Funded by firms like Radius Ventures, OrbiMed Advisors, MPM BioEquities and others Over 130 issued patents (including RM and other areas)

Stem Cells Developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform

Therapeutic areas - multiple disease indications in the areas of inflammatory and immune neurological cardiovascular disease.

Alliances Development & commercialisation partnerships with Bristol-Myers Squibb (BMS), Angiotech

Pharma and Pfizer



Several promising unlisted companies

Organogenesis, USA: Largest by revenue With $100mn revenue in 2011, largest

regenerative company in the world Founded in 1985, listed in 1986, went

private in 2002 Got FDA approvaal for flagship product

Apligraf in 1998, ahead of its time Acquired Dermagraft from Shire Plc in

Jan’14 for staged payments upto $300mn

Stem Cells Apligraf is a matrix of cow collagen,

human fibroblasts and keratinocyte stem cells (from discarded circumcisions)

Therapeutic Areas Wound healing (Apligraf) Oral regeneration (Gintuit)


Gamida (Isreal): Leader in stem cell expansion tech Has developed a large number of platform

technologies to expand functional cell populations

Backed by strategics and venture funds: Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva Pharma, Amgen, Denali Ventures and Auriga Ventures

Stem Cells UCB stem cellsTherapeutic Areas Blood cancer, solid tumours, autoimmune

and metabolic disorders Its lead product StemEx is in Phase III for

treatment for bone marrow transplant for blood cancer, and will be launched soon

39

Stem Cell Banks

China Cord Blood Corporation: Largest Chinese Stem Cell Bank China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell

processing, and stem cell storage services Listed on NYSE in 2009, when it raised $20mn. Leading US PE fund KKR invested $65mn in

CCBC in Apr’12

Business profile Accumulated subscriber base reached 359,487 by Dec’13 Under PRC government regulations, only one licensed cord blood bank is permitted to

operate in each licensed region and only seven licenses have been authorized as of today• The only operator with multiple licenses, with access to 4* of the 7 authorized licenses. It has

its own centres in Beijing, Guangdong, and Zhejiang; and holds equity in another bank


40

Stem Cell Banks

Cordlife Group, Singapore The first cord blood bank to be set up in Singapore (May 2001) Listed on Singapore Exchange Main Board on 29 March 2012 Has done aggressive investments recently. The Group acquired 10% equity in China Cord

Blood Corporation, one of the top operators in China. It also accquired 32% stake in StemLife Bhd, Malaysia. It also acquired parts of Asian business of Australia’s Cordlife Limited.

Business profile Owns and operates full processing and cryopreservation storage facilities across Asia, namely

in Singapore, Hong Kong, India, Indonesia and The Philippines


41

Service Companies

Hope Medical Group, China Group of five hospitals in China certified by The Chinese Ministry of Health to provide adult

stem cell and Cancer immunotherapy treatments for local and global patients. The Hospitals are

Wuxi Peoples Hospital, Jiangsu: 1870 beds. It is also Ministry of Health stem cell technical training base Mary’s Orthopedic Hospital, Beijing: 260 beds, focusses on stem cell treatment in bone & cartilage injuries; bone

coloboma & bone non union; ischemic necrosis of femoral head; osteoarthritis; Erb’s disease; neck, back pain caused by Intervertebral Disc Degeneration etc.

Beijing Zhenguo Tumor Rehabilitation Hospital: 300 beds, focusses on cancer and tumour Guangzhou Cancer Center: 1000 beds Hengyang Stem cell and cancer center: 1500 beds, offers Hemopoietic stem cell transplantation


Leading Indian Companies



Key Indian Players and their Focus in Sub-Sectors of Stem Cell Segment


Company Profile Banking Research Product

Reliance Life Sciences Pvt Ltd

It has in-house capabilities in research, development, commercial manufacturing, sales & marketing. The company is developing products in the domain of regenerative medicine (stem cell therapies, tissue engineered products, stem cell enriched repository services, assisted reproduction)

Cord Blood Repository offering both public and family banking services

Regenerative medicine – range of novel autologus and allogenic cell therapies and tissue engineered products

ReliNethra: Autologus limbal stem cell composite graft

CardioRel: Autologus cardiomyocytes

LifeCell International Pvt Ltd

LifeCell is India’s first & largest private stem cell bank and stem cells solutions provider. The company has a technological collaboration with CRYO-CELL International Inc. – the world’s first and largest stem cell bank

Umbilical cord blood & cord tissue; menstrual blood cell banking

TRICell Therapeutics: Research in autologus bone marrow for the treatment of non reconstructable critical limb ischemia; allogenic cord blood infusion in patients with Type I diabetes; burns and wound healing etc.


Key Indian Players and their Focus in Sub-Sectors of Stem Cell Segment


Company Profile Banking Research Product

Cryobanks International India Pvt Ltd

Founded in 2006, the company is a JV between Cryobanks International USA and RJ Corp, under the guidance of Dr. Naresh Trehan (Medanta). Approved by US FDA

Umbilical cord blood stem cell banking

Cryobanks is conducting research on the use of stem cells for several therapy areas like Diabetes, Alzheimer’s, Multiple Sclerosis, Cariology etc.

Stempeutics Research Pvt Ltd

The company is developing stem cell based medicinal products, with facilities in Bangalore, Manipal and Malaysia. The company has an alliance with Cipla for the marketing of its products. Its first product, for critical limb ischemia, is set to be commercialised soon

Derived from bone marrow

Stempeutics has 8 products in clinical trials, in Phase I and II stages. These are in the area of Cardiology, Diabetes, Osteo-arthritis, Liver and Critical Limb Ischemia

Stempeucel-CLI for critical limb ischemia is now set for a Phase III trial and a launch after that soon

OCT Therapies & Research Pvt Ltd

OCT is currently working on its first product: a WJ-MSC based approach towards advanced would care. The company has filed for patent, and is currently doing animal trials

WJ-MSC Its first product is currently in animal tests. OCT aims to start Phase 1 within a year

For mild to severe burns, and chronic ulcers. It is a topical application

Deals: Acquistions / Funding / Partnerships


46

Acquisitions and mergers


When Acquirer Acquired Valuation ($mn) Key AssetsApr'14 Neostem California Stem

Cell Incn.a Melapuldencel-T, which targets cancer initiating cells for melanoma, will

become NeoStem's most advanced product candidate. Will undergo Phase III in 2014

Apr'14 Fate Therapeutics, Inc Verio Therapeutics Inc

n.a Developing drug candidates targeting the activation of endogenous stem cells

Mar'14 Intrexon Corporation Medistem, Inc n.a Pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies

Jan’14 Organogenesis Dermagraft from Shire Plc

300 Shire Plc exited RM business it acquired in 2011 when it purchased Advanced BioHealing. Organogenesis has $100mn+ revenue from Apligraf, and gets another $70mn from this deal, consolidating its No 1 position in the US advanced wound care market.

Oct'13 StemCells, Inc. Patents from Neurospheres Holdings Ltd

n.a The portfolio broadly claims the manufacture and proliferation of purified populations of human neural stem cells and their use as therapeutics and as tools for drug discovery

Apr'13 Stem Cell Therapeutics CorpTrillium Therapeutics Inc

Merger Immunotherapy and cancer stem cell research

Nov'12 Smith & Nephew plc Healthpoint Biotherapeutic

782 Bioactive debridement, dermal repair and regeneration wound care treatments

Jun'12 Royal DSM Kensey Nash 360 Biomedical equipment following advances in regenerative medicine and tissue engineering

Apr'12 Shire PLC Pervasis Therapeutics

200 Vascugel, a biodegradable implant containing human endothelial cells in Phase II testing to prevent hemodialysis vascular access failure in patients with end-stage renal disease (ESRD)

Feb'12 Cytomedix Inc Aldagen Inc 40 Regenerative therapies for wound care, inflammation and blood vessel developmen

Jan'12 Mediware Information Systems Inc

Transtem LLC. Software for managing the collection and transplantation of adult stem cells for cellular therapy and medical research

Oct'11 NeoStem Inc Amorcyte n.a AMR-001, a stem cell treatment being evaluated for the treatment of acute myocardial infarction

47

PE deals


When Investor Target Deal Size ($mn)

Country

Dec'13 Special Situations Funds, Ridgeback Capital, Merlin Nexus, Sabby Capital, venBio, Opaleye Management and HSMR Advisors.

Stem Cell Therapeutics Corp

30 USA

Nov'13 Sheridan Legacy Group Progenicare n.a USA

Aug'13Ballast Point Ventures and River Cities Capital Funds TissueTech Inc. 10

USA

Jul'13 Wales Life Sciences Investment Fund ReNeuron 20 Wales

Feb'13Helion Lifecell International Pvt

Ltd 7 India

Apr'12KKR China Cord Blood Corp

65 China

Jul'11

Johnson & Johnson Development Corp., Sanderling Ventures and Asset Management Co.

Viacyte Inc

11 USA

Apr'11

Tactics II Stem Cell Ventures, Sam Zell's Equity Group Investments LLC, Sixth Floor Investors LP and G Force Investments LLC

Cellular Dynamics International, Inc

30 USA

Apri'11 PBM Capital Group, L.P GigaCyte n.a USA

48

Disclaimer


Copyright© 2014 India Business Reports• All rights reserved. No part of this publication may be reproduced or utilized, stored in a retrieval system, or transmitted in any form or

by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of India Business Reports (“IBR”)

Legal Notices and Disclaimer • None of IBR, its partners, employees, affiliates, representatives or advisors make any representation or warranty, expressed or implied,

as to the accuracy or completeness of any of the information contained herein, including any opinion or any other written or oral communication transmitted or made available. Each recipient of such information expressly disclaims any and all liability relating to or resulting from the use of such information and communications by a recipient or any of its affiliates, advisors or representatives. In particular, no representation or warranty is given as to the achievement or reasonableness of any future projections, estimates or statements about the future prospects of any of the companies.

• This document is for the use of the persons who receive it directly from IBR. Recipients agree that all of the information contained in it is of a confidential nature, and that they will not, directly or indirectly, disclose any such information without the prior written consent of IBR.

Confidentiality• In consideration of you receiving a copy of this document, you agree to keep confidential the contents of this document and shall not,

without the prior written approval India Business Reports (“IBR”) disclose to any person the whole or any part of the information contained in, or associated with this document.

Thank You


[email protected]